What is the appropriate treatment for a patient with hyperkalemia?

Treatment of Hyperkalemia

For acute hyperkalemia with ECG changes or severe elevation, immediately administer intravenous calcium gluconate to stabilize the cardiac membrane, followed by insulin/glucose and inhaled beta-agonists to shift potassium intracellularly, then initiate strategies to remove potassium from the body using diuretics, newer potassium binders (patiromer or sodium zirconium cyclosilicate), or dialysis for refractory cases. 1

Acute Hyperkalemia Management

Immediate Stabilization (Within 1-3 Minutes)

• IV calcium gluconate is the first-line agent when ECG changes are present (peaked T waves, prolonged QRS complexes) 1
  • Acts within 1-3 minutes to stabilize cardiac membranes
  • Does NOT lower serum potassium levels
  • Repeat dose in 5-10 minutes if no effect observed 1

Shift Potassium Intracellularly (Within 30 Minutes)

After cardiac stabilization, use agents that redistribute potassium:

• IV insulin plus glucose - acts within 30 minutes 1
• Inhaled beta-agonists (salbutamol) - acts within 30 minutes 1
• IV sodium bicarbonate - only in patients with concurrent metabolic acidosis 1

Critical caveat: These agents only shift potassium temporarily and do NOT remove it from the body. Total body potassium remains elevated.

Remove Potassium from the Body

• Diuretics (loop or thiazide) - if patient is not volume depleted 1, 2
• Newer potassium binders:
  • Sodium zirconium cyclosilicate (SZC) - can reduce potassium within 1-2 hours; up to three 10-g doses within 10 hours in emergency settings 1
  • Patiromer - onset approximately 7 hours 1
• Hemodialysis - for severe, refractory cases or patients with kidney failure 1, 2

Chronic Hyperkalemia Management

The primary goal is to normalize and maintain potassium levels while continuing life-saving therapies like RAASi, rather than discontinuing these medications. 3, 4

Step-by-Step Algorithm

1. Correct reversible factors first 3:

   • Review and remove unnecessary medications causing hyperkalemia
   • Address dietary potassium intake (focus on reducing non-plant sources, not restricting all potassium-rich foods) 3, 5
   • Treat constipation
   • Correct metabolic acidosis
   • Optimize diuretic therapy 1

2. If no reversible factors exist, initiate treatment to prevent recurrence 3:

   • Newer potassium binders are preferred:
     • Patiromer: Maintains normokalemia for up to 12 months; dose 8.4g once daily, separate from other medications by 3+ hours 1
     • SZC: Effective at maintaining normokalemia over 12 months; once-daily 5-10g dose 1
   • These agents allow continuation of RAASi therapy at optimal doses 3, 4, 6

3. Avoid down-titration or discontinuation of RAASi/MRAs 5, 4, 6:

   • Approximately 50% of patients on RAASi experience recurrent hyperkalemia annually 6
   • Reducing or stopping RAASi increases risk of adverse cardiovascular and renal outcomes or death 4, 6
   • Treat the hyperkalemia, not by stopping the life-saving medication

Monitoring Strategy

• Check potassium 7-10 days after starting or increasing RAASi doses 1
• More frequent monitoring in high-risk patients (CKD, diabetes, heart failure, history of hyperkalemia) 1
• Use risk stratification tools to identify patients at risk for recurrence 3

Key Differences Between Newer Binders

Patiromer 1:

• Onset: ~7 hours
• Must separate from other medications by 3+ hours
• Most common side effects: GI symptoms (constipation, diarrhea), hypomagnesemia, rare hypercalcemia
• Exchanges calcium for potassium

Sodium Zirconium Cyclosilicate (SZC) 1:

• Onset: 1-2 hours (faster than patiromer)
• Can be used in acute settings
• Most common side effects: hypokalemia, dose-dependent edema
• May increase serum bicarbonate (beneficial in metabolic acidosis)

Common Pitfalls to Avoid

1. Do NOT rely solely on ECG findings - they are variable and not as sensitive as laboratory testing for detecting hyperkalemia 1

2. Do NOT use sodium polystyrene sulfonate (SPS) chronically - older resin with poor tolerance, GI side effects, and falling out of favor 2, 7

3. Do NOT restrict all potassium-rich foods - the evidence for dietary restriction effectiveness is lacking; instead, focus on reducing non-plant sources of potassium 3, 5

4. Do NOT discontinue RAASi as first-line management - this increases mortality and morbidity risk in patients with heart failure and proteinuric kidney disease 5, 4, 6

5. Remember that 20% of patients will have hyperkalemia recurrence - proactive management with newer binders prevents the need to interrupt life-saving therapies 3